{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:55:03Z","timestamp":1753883703648,"version":"3.41.2"},"reference-count":32,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T00:00:00Z","timestamp":1653782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>During pregnancy, there is no established treatment for idiopathic hyperaldosteronism (IHA), the most common form of primary aldosteronism due to bilateral adrenal hyperplasia. Here, we report the case of a pregnant patient with IHA who was successfully treated with esaxerenone, a nonsteroidal mineralocorticoid receptor (MR) antagonist. A 39-year-old woman was diagnosed with IHA and commenced on nifedipine 20 mg daily because she desired to be pregnant. After 1 year, she became pregnant. Her blood pressure was well controlled until 34 weeks of gestation when her home blood pressure became elevated up to 140\/90 mmHg. Although the dose of nifedipine was increased to 80 mg daily, her blood pressure increased to 151\/97 mmHg, and urinary test showed proteinuria of 2+ in 35 weeks of gestation. She was diagnosed with superimposed preeclampsia (SPE) and additionally treated with esaxerenone. Her blood pressure decreased to 120-140\/98-100 mmHg and the proteinuria improved to \u00b1. A successful cesarean section at 37 weeks resulted in the delivery of a healthy baby boy. Her blood pressure was well controlled although esaxerenone was discontinued 2 weeks after the delivery. This is the first case of a pregnant woman who was safely treated with esaxerenone despite being a female at advanced maternal age who had been diagnosed with IHA and developed SPE. Further studies are needed to investigate the efficacy and safety of nonsteroidal selective MR antagonist in similar pregnant patients with IHA to establish better treatment strategy for these patients.<\/jats:p>","DOI":"10.1210\/jendso\/bvac085","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T21:12:58Z","timestamp":1654031578000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case of a Pregnant Woman With Primary Aldosteronism and Superimposed Preeclampsia Treated With Esaxerenone"],"prefix":"10.1210","volume":"6","author":[{"given":"Kaoru","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-2319","authenticated-orcid":false,"given":"Satoshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotaka","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihori","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-7704","authenticated-orcid":false,"given":"Yasufumi","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Bokuda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiro","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University , 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2022,5,29]]},"reference":[{"issue":"2","key":"2022061909002458200_CIT0001","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/AOG.0000000000002114","article-title":"Pregnancy-related mortality in the United States, 2011-2013","volume":"130","author":"Creanga","year":"2017","journal-title":"Obstet Gynecol."},{"issue":"2","key":"2022061909002458200_CIT0002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.emc.2019.01.008","article-title":"Hypertensive disorders of pregnancy","volume":"37","author":"Wilkerson","year":"2019","journal-title":"Emerg Med Clin North Am."},{"issue":"10","key":"2022061909002458200_CIT0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1056\/NEJM199809033391004","article-title":"Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension","volume":"339","author":"Sibai","year":"2022","journal-title":"N Engl J Med."},{"issue":"2","key":"2022061909002458200_CIT0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10641955.2014.982329","article-title":"Maternal and fetal outcome in de novo preeclampsia in comparison to superimposed preeclampsia: a two-year observational study","volume":"34","author":"Rezk","year":"2015","journal-title":"Hypertens Pregnancy."},{"issue":"4","key":"2022061909002458200_CIT0005","doi-asserted-by":"crossref","first-page":"515.e1","DOI":"10.1016\/j.ajog.2014.10.1090","article-title":"Expectant management of mild preeclampsia versus superimposed preeclampsia up to 37 weeks","volume":"212","author":"Valent","year":"2015","journal-title":"Am J Obstet Gynecol."},{"issue":"6","key":"2022061909002458200_CIT0006","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation."},{"issue":"4","key":"2022061909002458200_CIT0007","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","article-title":"Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats","volume":"43","author":"Nishiyama","year":"2004","journal-title":"Hypertension"},{"issue":"11","key":"2022061909002458200_CIT0008","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41440-018-0093-6","article-title":"Microvascular endothelial function is impaired in patients with idiopathic hyperaldosteronism","volume":"41","author":"Kishimoto","year":"2018","journal-title":"Hypertens Res."},{"issue":"2","key":"2022061909002458200_CIT0009","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension."},{"key":"2022061909002458200_CIT0010","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/01.hjh.0000467473.21331.70","article-title":"prevalence of secondary hypertension in young hypertensive adults","volume":"33","author":"Camelli","year":"2015","journal-title":"J Hypertens."},{"issue":"2","key":"2022061909002458200_CIT0011","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1161\/HYP.0000000000000208","article-title":"Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association","volume":"79","author":"Garovic","year":"2022","journal-title":"Hypertension"},{"key":"2022061909002458200_CIT0012","first-page":"1122","article-title":". Hypertension in pregnancy: report of the American college of obstetricians and gynecologists\u2019 task force on hypertension in pregnancy","volume":"122","author":"Roberts","year":"2013","journal-title":"Obstet Gynecol."},{"author":"National Institute for Health and Care Excellence.","key":"2022061909002458200_CIT0013","article-title":"Hypertension in pregnancy: diagnosis and management: NICE guideline [NG133]. Accessed June 10, 2022"},{"issue":"4","key":"2022061909002458200_CIT0014","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.preghy.2015.08.003","article-title":"Primary aldosteronism and pregnancy","volume":"5","author":"Morton","year":"2015","journal-title":"Pregnancy Hypertens."},{"issue":"8","key":"2022061909002458200_CIT0015","first-page":"943","article-title":"Plasma progesterone and aldosterone in pregnancy","volume":"112","author":"Ledoux","year":"1975","journal-title":"Can Med Assoc J."},{"issue":"11","key":"2022061909002458200_CIT0016","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1172\/JCI107462","article-title":"A study of angiotensin II pressor response throughout primigravid pregnancy","volume":"52","author":"Gant","year":"1973","journal-title":"J Clin Invest."},{"issue":"3","key":"2022061909002458200_CIT0017","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1139\/y82-060","article-title":"Saliva progesterone throughout the menstrual cycle and late pregnancy","volume":"60","author":"Connor","year":"1982","journal-title":"Can J Physiol Pharmacol."},{"issue":"1","key":"2022061909002458200_CIT0018","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/EJE-14-0444","article-title":"Mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy","volume":"172","author":"Riester","year":"2015","journal-title":"Eur J Endocrinol."},{"article-title":"Japan Endocrine Society Clinical practice guideline for the diagnosis and management of primary aldosteronism 2021","author":"Naruse","key":"2022061909002458200_CIT0019","doi-asserted-by":"crossref","DOI":"10.1507\/endocrj.EJ21-0508"},{"issue":"1","key":"2022061909002458200_CIT0020","first-page":"S1","article-title":"Hypertension in pregnancy: diagnosis and management","volume":"77","author":"National Institute for Health and Care Excellence","year":"2010","journal-title":"Am J Obs Gynecol"},{"article-title":"maternity and neonatal clinical guideline","year":"2017","author":"Queensland Health. Queensland clinical guidelines:","key":"2022061909002458200_CIT0021"},{"issue":"50","key":"2022061909002458200_CIT0022","doi-asserted-by":"crossref","first-page":"31334","DOI":"10.1016\/S0021-9258(18)31697-1","article-title":"Angiotensinogen-deficient mice with hypotension","volume":"269","author":"Tanimoto","year":"1994","journal-title":"J Biol Chem."},{"issue":"7","key":"2022061909002458200_CIT0023","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1073\/pnas.92.7.2735","article-title":"Genetic control of blood pressure and the angiotensinogen locus","volume":"92","author":"Kim","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2022061909002458200_CIT0024","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/tera.1420440503","article-title":"ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection","volume":"44","author":"Barr","year":"1991","journal-title":"Teratology"},{"issue":"6","key":"2022061909002458200_CIT0025","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1471-0528.2004.00525.x","article-title":"Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases","volume":"112","author":"Serreau","year":"2005","journal-title":"BJOG An Int J Obstet Gynaecol"},{"issue":"700","key":"2022061909002458200_CIT0026","doi-asserted-by":"crossref","first-page":"E778","DOI":"10.3399\/bjgp20X712997","article-title":"Pregnancy protection and pregnancies in women prescribed ACE inhibitors or ARBs: a cross-sectional study in primary care","volume":"70","author":"Lovegrove","year":"2020","journal-title":"Br J Gen Pract."},{"issue":"5","key":"2022061909002458200_CIT0027","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1447-0756.2001.tb01268.x","article-title":"Pregnancy complicated with Bartter\u2019s syndrome: a case report","volume":"27","author":"Nohira","year":"2001","journal-title":"J Obstet Gynaecol Res."},{"issue":"2","key":"2022061909002458200_CIT0028","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/HYPERTENSIONAHA.111.187237","article-title":"Eplerenone use in primary aldosteronism during pregnancy","volume":"59","author":"Cabassi","year":"2012","journal-title":"Hypertension."},{"issue":"16","key":"2022061909002458200_CIT0029","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.1073\/pnas.95.16.9424","article-title":"Mineralocorticoid receptor knockout mice: Pathophysiology of Na+ metabolism","volume":"95","author":"Berger","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"2022061909002458200_CIT0030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: First global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs."},{"issue":"10","key":"2022061909002458200_CIT0031","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/1873-3468.13746","article-title":"Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150)","volume":"594","author":"Takahashi","year":"2020","journal-title":"FEBS Lett."},{"author":"Pharmaceuticals and Medical Devices Agency","key":"2022061909002458200_CIT0032"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvac085\/43887698\/bvac085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/8\/bvac085\/44136611\/bvac085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/8\/bvac085\/44136611\/bvac085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T09:01:04Z","timestamp":1655629264000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvac085\/6594684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,29]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvac085","relation":{},"ISSN":["2472-1972"],"issn-type":[{"type":"electronic","value":"2472-1972"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,29]]},"article-number":"bvac085"}}